MicroVision MOVIA lidar gains support on NVIDIA DRIVE AGX platform
Investing.com - TD Cowen maintained its Buy rating and €250.00 price target on UCB SA (BR:UCB) (OTC:UCBJY) on Monday, following positive feedback from hidradenitis suppurativa (HS) specialists about the company’s Bimzelx treatment.
The research firm highlighted encouraging real-world efficacy data for Bimzelx, noting that clinicians reported minimal concerns about the drug’s tolerability profile in treating HS, a chronic inflammatory skin condition.
TD Cowen’s analysis suggests Bimzelx has become the preferred treatment option among specialists due to significant unmet needs in the HS market, positioning the drug for potential widespread adoption.
The firm projects Bimzelx represents a substantial €3 billion-plus opportunity in the HS market, contributing to UCB’s growth trajectory in coming years.
UCB currently trades at approximately 16 times TD Cowen’s estimated 2026 earnings per share, which the firm considers attractive given the company’s growth prospects driven by Bimzelx’s expanding market presence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.